Immunexpress

Executive Summary

Immunexpress is a privately held biotechnology company specializing in rapid molecular diagnostics for sepsis. Its flagship product, SeptiCyte RAPID, uniquely analyzes the host immune response to deliver actionable results in approximately one hour, addressing a critical unmet need for timely sepsis diagnosis. Unlike traditional pathogen detection methods, this approach enables clinicians to rule out sepsis quickly, potentially reducing unnecessary antibiotic use and improving patient outcomes. Based in Seattle, WA, and Brisbane, Australia, the company has established a foothold in the diagnostics space, though it remains private with limited public financial disclosures. The platform's speed and specificity position it as a promising tool in emergency and critical care settings.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for SeptiCyte RAPID Expanded Indication70% success
• Q2 2026Strategic Partnership with a Major Hospital Network or Diagnostics Distributor50% success
• Q3 2026Publication of Pivotal Clinical Validation Study in a Peer-Reviewed Journal80% success